Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-04-30

Study Completion Date

2020-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To document the clinical outcomes of cancer patients who received the Guardant360® test and agree to share their records with Guardant Health.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

NCT06523868

Cancer Diagnosis

RECRUITING NA

REFLECTION: A Clinical Practice Learning Program for Galleri®

NCT05205967

Early Detection of Cancer Cancer

ACTIVE_NOT_RECRUITING

The Galleri® Community Research Program

NCT06603259

Data Collection

ENROLLING_BY_INVITATION

Using a Geriatric Oncology Assessment to Link With Services

NCT02906592

Cancer

COMPLETED

A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor

NCT00803894

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an observational study of clinical outcomes to be conducted in the United States. Patients with a diagnosis of Stage 3-4 advanced cancer who possess specific pathway mutations identified by the Guardant360® test will be eligible to enroll in the study. Patients will be recruited by telephone or email and/or through the Guardant Health Patient Portal to determine interest in the study. Should patients be interested in contributing to this registry study, they will be prompted to consent via a commercial service for patients to request, manage, and view their medical records. Enrolled participants will be requested to release copies of their medical records for review by the principal investigator. Study adminsitrators will abstract participant demographics, cancer-related therapies, and clinical outcomes for analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Hematologic Malignancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults (≥ 18 years old) with a diagnosis of Stage 3 or Stage 4 cancer (non-hematologic malignancy). Patients with advanced cancers not typically staged 1-4 (such as extensive stage small lung cancer) may be enrolled.
* Results from Guardant360® test
* Patient has previously provided contact information (either email or phone) to Guardant Health.
* Able and wiling to complete the informed consent process.
* Willingness to consent to the release of medical records.
* Willingness to provide Medical Records Release

Exclusion Criteria

* Unwilling or unable to provide written informed consent.
* Unable to understand English.
* Diagnosis of NSCLC
* Guardant 360® test results released to the patient's physician no less than 14 days and no greater than 60 days prior to initial patient contact.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No